id:"swepub:oai:DiVA.org:uu-196027"
Sökning: id:"swepub:oai:DiVA.org:uu-196027" > Assessment of glyce...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Schneck, Karen B. (författare)
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study : application of a semi-mechanistic, integrated glucose-insulin-glucagon model
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
- 2012-12-22
- Springer Science and Business Media LLC,2013
- printrdacarrier
Nummerbeteckningar
- LIBRIS-ID:oai:DiVA.org:uu-196027
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-196027URI
- https://doi.org/10.1007/s10928-012-9287-8DOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- A proof of concept study was conducted to investigate the safety and tolerability of a novel oral glucokinase activator, LY2599506, during multiple dose administration to healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). To analyze the study data, a previously established semi-mechanistic integrated glucose-insulin model [1-5] was extended to include characterization of glucagon dynamics. The model captured endogenous glucose and insulin dynamics, including the amplifying effects of glucose on insulin production and of insulin on glucose elimination, as well as the inhibitory influence of glucose and insulin on hepatic glucose production. The hepatic glucose production in the model was increased by glucagon and glucagon production was inhibited by elevated glucose concentrations. The contribution of exogenous factors to glycemic response, such as ingestion of carbohydrates in meals, was also included in the model. The effect of LY2599506 on glucose homeostasis in subjects with T2DM was investigated by linking a one-compartment, pharmacokinetic model to the semi-mechanistic, integrated glucose-insulin-glucagon system. Drug effects were included on pancreatic insulin secretion and hepatic glucose production. The relationships between LY2599506, glucose, insulin, and glucagon concentrations were described quantitatively and consequently, the improved understanding of the drug-response system could be used to support further clinical study planning during drug development, such as dose selection.
Ämnesord och genrebeteckningar
- Glucokinase activator
- LY2599506
- Pharmacokinetics
- Pharmacodynamics
- Semi-mechanistic
- Glucose-insulin-glucagon model
- Diabetes mellitus
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Zhang, Xin (författare)
- Bauer, Robert (författare)
- Karlsson, Mats O.Uppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)matskarl (författare)
- Sinha, Vikram P. (författare)
- Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Journal of Pharmacokinetics and Pharmacodynamics: Springer Science and Business Media LLC40:1, s. 67-801567-567X1573-8744
Internetlänk
Hitta via bibliotek
- Journal of Pharmacokinetics and Pharmacodynamics (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Schneck, Karen B ...
- Zhang, Xin
- Bauer, Robert
- Karlsson, Mats O ...
- Sinha, Vikram P.
- Artiklar i publikationen
- Journal of Pharm ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
